Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 83

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Leveraging the Gut to Treat Metabolic Disease

Gimeno, Ruth E., Briere, Daniel A., Seeley, Randy J. · 2020 · Cell Metabolism

Abstract

Twenty-five years ago, the future of treating obesity and diabetes focused on end organs known to be involved in energy balance and glucose regulation, including the brain, muscle, adipose tissue and pancreas. Today, the most effective therapies are focused around the gut. This includes surgical options, such as vertical sleeve gastrectomy and Roux-en-Y gastric bypass, that can produce sustained weight loss and diabetes remission, but also extends to pharmacological treatments that simulate or amplify various signals that come from the gut. The purpose of this review is to discuss the wealth of approaches currently under development that seek to further leverage the gut as a source of novel therapeutic opportunities with the hope that we can achieve the effects of surgical interventions with less invasive and more scalable solutions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2020.02.014

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 64 references

Research works printed but not linked: 185

  1. Aaboe, 2009, KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 94, 603, 10.1210/jc.2008-1731 · DOI
  2. Aaboe, 2010, Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus, Diabetes Obes. Metab., 12, 323, 10.1111/j.1463-1326.2009.01167.x · DOI
  3. Addy, 2016, Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus, Clin. Ther., 38, 516, 10.1016/j.clinthera.2015.12.020 · DOI
  4. Adrian, 1985, Human distribution and release of a putative new gut hormone, peptide YY, Gastroenterology, 89, 1070, 10.1016/0016-5085(85)90211-2 · DOI · Paper page
  5. Adrian, 1986, Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man, J. Clin. Endocrinol. Metab., 63, 803, 10.1210/jcem-63-4-803 · DOI
  6. Ahlqvist, 2013, Link between GIP and osteopontin in adipose tissue and insulin resistance, Diabetes, 62, 2088, 10.2337/db12-0976 · DOI · Paper page
  7. Al-Najim, 2018, Food Intake and Eating Behavior After Bariatric Surgery, Physiol. Rev., 98, 1113, 10.1152/physrev.00021.2017 · DOI · Paper page
  8. Albaugh, 2019, Role of Bile Acids and GLP-1 in Mediating the Metabolic Improvements of Bariatric Surgery, Gastroenterology, 156, 1041, 10.1053/j.gastro.2018.11.017 · DOI · Paper page
  9. Arafat, 2013, Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?, Diabetologia, 56, 588, 10.1007/s00125-012-2803-y · DOI
  10. Araki, 2012, GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes, Diabetes Obes. Metab., 14, 271, 10.1111/j.1463-1326.2011.01525.x · DOI
  11. Arora, 2017, Diabetes-associated microbiota in fa/fa rats is modified by Roux-en-Y gastric bypass, ISME J., 11, 2035, 10.1038/ismej.2017.70 · DOI
  12. Aulinger, 2014, Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade, Diabetes, 63, 1079, 10.2337/db13-1455 · DOI
  13. Azevedo, 2016, Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity, J. Med. Chem., 59, 8868, 10.1021/acs.jmedchem.6b00685 · DOI
  14. Behary, 2019, Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study, Diabetes Care, 42, 1446, 10.2337/dc19-0449 · DOI
  15. Boland, 2019, Combined loss of GLP-1R and Y2R does not alter progression of high-fat diet-induced obesity or response to RYGB surgery in mice, Mol. Metab., 25, 64, 10.1016/j.molmet.2019.05.004 · DOI
  16. Boylan, 2015, Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice, Am. J. Physiol. Endocrinol. Metab., 309, E1008, 10.1152/ajpendo.00345.2015 · DOI · Paper page
  17. Briere, 2015, Novel Small Molecule Agonist of TGR5 Possesses Anti-Diabetic Effects but Causes Gallbladder Filling in Mice, PLoS ONE, 10, e0136873, 10.1371/journal.pone.0136873 · DOI
  18. Briere, 2018, Mechanisms to Elevate Endogenous GLP-1 Beyond Injectable GLP-1 Analogs and Metabolic Surgery, Diabetes, 67, 309, 10.2337/db17-0607 · DOI
  19. Brown, 2012, Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist, ACS Med. Chem. Lett., 3, 726, 10.1021/ml300133f · DOI
  20. Calara, 2005, A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4), Clin. Ther., 27, 210, 10.1016/j.clinthera.2005.02.008 · DOI
  21. Capozzi, 2019, β Cell tone is defined by proglucagon peptides through cAMP signaling, JCI Insight, 4, 10.1172/jci.insight.126742 · DOI · Paper page
  22. Chambers, 2017, The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice, Cell Metab., 25, 927, 10.1016/j.cmet.2017.02.008 · DOI · Paper page
  23. Chen, 2016, GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space, Bioorg. Med. Chem. Lett., 26, 5603, 10.1016/j.bmcl.2016.10.074 · DOI
  24. Chepurny, 2018, Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors, Sci. Rep., 8, 3749, 10.1038/s41598-018-22106-1 · DOI
  25. Chisholm, 2002, Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures, Am. J. Physiol. Endocrinol. Metab., 283, E311, 10.1152/ajpendo.00434.2001 · DOI · Paper page
  26. Christensen, 2014, Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 99, E418, 10.1210/jc.2013-3644 · DOI
  27. Christiansen, 2018, The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon, Am. J. Physiol. Gastrointest. Liver Physiol., 315, G53, 10.1152/ajpgi.00346.2017 · DOI · Paper page
  28. Chukir, 2018, Pharmacotherapy for obesity in individuals with type 2 diabetes, Expert Opin. Pharmacother., 19, 223, 10.1080/14656566.2018.1428558 · DOI
  29. Cohen, 2003, Oxyntomodulin suppresses appetite and reduces food intake in humans, J. Clin. Endocrinol. Metab., 88, 4696, 10.1210/jc.2003-030421 · DOI · Paper page
  30. Connolly, 2018, Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials, J. Clin. Transl. Hepatol., 6, 264
  31. Cox, 2016, Characterization and quantification of oxyntomodulin in human and rat plasma using high-resolution accurate mass LC-MS, Bioanalysis, 8, 1579, 10.4155/bio-2016-0012 · DOI
  32. Cox, 2016, Design, Synthesis, and Evaluation of Novel and Selective G-protein Coupled Receptor 120 (GPR120) Spirocyclic Agonists, ACS Med. Chem. Lett., 8, 49, 10.1021/acsmedchemlett.6b00360 · DOI
  33. D’Alessio, 1990, Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men, Diabetes, 39, 1198, 10.2337/diab.39.10.1198 · DOI
  34. Dar, 2012, GLP-1 response to a mixed meal: what happens 10 years after Roux-en-Y gastric bypass (RYGB)?, Obes. Surg., 22, 1077, 10.1007/s11695-012-0624-1 · DOI
  35. Day, 2009, A new glucagon and GLP-1 co-agonist eliminates obesity in rodents, Nat. Chem. Biol., 5, 749, 10.1038/nchembio.209 · DOI · Paper page
  36. De Silva, 2011, The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans, Cell Metab., 14, 700, 10.1016/j.cmet.2011.09.010 · DOI · Paper page
  37. Deacon, 2016, Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas, Diabetes Obes. Metab., 18, 333, 10.1111/dom.12610 · DOI · Paper page
  38. Demssie, 2012, Metabolic outcomes 1 year after gastric bypass surgery in obese people with type 2 diabetes, Med. Princ. Pract., 21, 125, 10.1159/000331793 · DOI
  39. Douros, 2018, Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor, Diabetes, 67, 1504, 10.2337/db18-0081 · DOI
  40. Dumont, 1995, Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34]peptide YY and [125I]peptide YY3-36 as selective Y1 and Y2 radioligands, J. Pharmacol. Exp. Ther., 272, 673, 10.1016/S0022-3565(25)24459-7 · DOI
  41. Ellingsgaard, 2011, Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells, Nat. Med., 17, 1481, 10.1038/nm.2513 · DOI · Paper page
  42. Falkén, 2011, Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides, J. Clin. Endocrinol. Metab., 96, 2227, 10.1210/jc.2010-2876 · DOI · Paper page
  43. Farb, 2017, Regulation of Endogenous (Male) Rodent GLP-1 Secretion and Human Islet Insulin Secretion by Antagonism of Somatostatin Receptor 5, Endocrinology, 158, 3859, 10.1210/en.2017-00639 · DOI
  44. Finan, 2015, A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents, Nat. Med., 21, 27, 10.1038/nm.3761 · DOI · Paper page
  45. Fjellström, 2015, Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents, PLoS ONE, 10, e0145849, 10.1371/journal.pone.0145849 · DOI
  46. Frimurer, 2017, Model-Based Discovery of Synthetic Agonists for the Zn2+-Sensing G-Protein-Coupled Receptor 39 (GPR39) Reveals Novel Biological Functions, J. Med. Chem., 60, 886, 10.1021/acs.jmedchem.6b00648 · DOI
  47. García-Pérez, 2013, Adherence to therapies in patients with type 2 diabetes, Diabetes Ther., 4, 175, 10.1007/s13300-013-0034-y · DOI · Paper page
  48. Garibay, 2018, β Cell GLP-1R Signaling Alters α Cell Proglucagon Processing after Vertical Sleeve Gastrectomy in Mice, Cell Rep., 23, 967, 10.1016/j.celrep.2018.03.120 · DOI
  49. Gasoyan, 2019, Reasons for underutilization of bariatric surgery: The role of insurance benefit design, Surg. Obes. Relat. Dis., 15, 146, 10.1016/j.soard.2018.10.005 · DOI · Paper page
  50. Geary, 1992, Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men, Am. J. Physiol., 262, R975
  51. Geloneze, 2003, Ghrelin: a gut-brain hormone: effect of gastric bypass surgery, Obes. Surg., 13, 17, 10.1381/096089203321136539 · DOI · Paper page
  52. Gerstein, 2019, Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet, 394, 121, 10.1016/S0140-6736(19)31149-3 · DOI · Paper page
  53. Gletsu-Miller, 2013, Mineral malnutrition following bariatric surgery, Adv. Nutr., 4, 506, 10.3945/an.113.004341 · DOI · Paper page
  54. Guida, 2018, Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY, Diabetes Obes. Metab., 20, 571, 10.1111/dom.13113 · DOI
  55. Günther, 2018, International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature, Pharmacol. Rev., 70, 763, 10.1124/pr.117.015388 · DOI · Paper page
  56. Guo, 2016, Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes, ACS Med. Chem. Lett., 7, 1107, 10.1021/acsmedchemlett.6b00314 · DOI
  57. Habib, 2013, Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells, Diabetologia, 56, 1413, 10.1007/s00125-013-2887-z · DOI · Paper page
  58. Hamdouchi, 2016, The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470), J. Med. Chem., 59, 10891, 10.1021/acs.jmedchem.6b00892 · DOI
  59. Hankir, 2017, Gastric Bypass Surgery Recruits a Gut PPAR-α-Striatal D1R Pathway to Reduce Fat Appetite in Obese Rats, Cell Metab., 25, 335, 10.1016/j.cmet.2016.12.006 · DOI
  60. Hansen, 2000, Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum, Am. J. Physiol. Endocrinol. Metab., 278, E1010, 10.1152/ajpendo.2000.278.6.E1010 · DOI
  61. Hauge-Evans, 2009, Somatostatin secreted by islet delta-cells fulfills multiple roles as a paracrine regulator of islet function, Diabetes, 58, 403, 10.2337/db08-0792 · DOI · Paper page
  62. Henderson, 2016, Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates, Diabetes Obes. Metab., 18, 1176, 10.1111/dom.12735 · DOI · Paper page
  63. Henry, 2013, Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers, J. Clin. Endocrinol. Metab., 98, 3446, 10.1210/jc.2013-1771 · DOI · Paper page
  64. Herman, 2006, Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes, J. Clin. Endocrinol. Metab., 91, 4612, 10.1210/jc.2006-1009 · DOI · Paper page
  65. Hernandez, 2018, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet, 392, 1519, 10.1016/S0140-6736(18)32261-X · DOI · Paper page
  66. Hirose, 2017, Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus, Bioorg. Med. Chem., 25, 4175, 10.1016/j.bmc.2017.06.007 · DOI
  67. Hjøllund, 2011, Dipeptidyl peptidase-4 inhibition increases portal concentrations of intact glucagon-like peptide-1 (GLP-1) to a greater extent than peripheral concentrations in anaesthetised pigs, Diabetologia, 54, 2206, 10.1007/s00125-011-2168-7 · DOI
  68. Højberg, 2009, Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes, Diabetologia, 52, 199, 10.1007/s00125-008-1195-5 · DOI · Paper page
  69. Holst, 2018, Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss, Surg. Obes. Relat. Dis., 14, 708, 10.1016/j.soard.2018.03.003 · DOI · Paper page
  70. Holzer, 2012, Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis, Neuropeptides, 46, 261, 10.1016/j.npep.2012.08.005 · DOI · Paper page
  71. Hornigold, 2018, A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice, Appetite, 127, 334, 10.1016/j.appet.2018.05.131 · DOI
  72. Iepsen, 2016, Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36, Eur. J. Endocrinol., 174, 775, 10.1530/EJE-15-1116 · DOI · Paper page
  73. Jordan, 2008, Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients, Clin. Pharmacol. Ther., 83, 281, 10.1038/sj.clpt.6100272 · DOI
  74. Kaku, 2016, Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study, Diabetes Obes. Metab., 18, 925, 10.1111/dom.12693 · DOI
  75. Kalinowski, 2017, Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass-results of a randomized clinical trial, Surg. Obes. Relat. Dis., 13, 181, 10.1016/j.soard.2016.08.025 · DOI
  76. Kassem, 2017, The Impact of Bariatric Surgery on Type 2 Diabetes Mellitus and the Management of Hypoglycemic Events, Front. Endocrinol. (Lausanne), 8, 37, 10.3389/fendo.2017.00037 · DOI
  77. Katz, 2011, Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects, Clin. Pharmacol. Ther., 90, 685, 10.1038/clpt.2011.169 · DOI
  78. Katz, 2012, Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes, Diabetes Obes. Metab., 14, 709, 10.1111/j.1463-1326.2012.01587.x · DOI
  79. Keitel, 2009, The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders, Hepatology, 50, 861, 10.1002/hep.23032 · DOI · Paper page
  80. Kim, 2018, Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21, Diabetes, 67, 1773, 10.2337/db17-1502 · DOI · Paper page
  81. Kjaergaard, 2019, PYY(3-36) and exendin-4 reduce food intake and activate neuronal circuits in a synergistic manner in mice, Neuropeptides, 73, 89, 10.1016/j.npep.2018.11.004 · DOI
  82. Kliewer, 2019, A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21, Cell Metab., 29, 246, 10.1016/j.cmet.2019.01.004 · DOI · Paper page
  83. Knop, 2017, Exenatide: pharmacokinetics, clinical use, and future directions, Expert Opin. Pharmacother., 18, 555, 10.1080/14656566.2017.1282463 · DOI
  84. Kojima, 1999, Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature, 402, 656, 10.1038/45230 · DOI · Paper page
  85. Kosinski, 2012, The glucagon receptor is involved in mediating the body weight-lowering effects of oxyntomodulin, Obesity (Silver Spring), 20, 1566, 10.1038/oby.2012.67 · DOI
  86. Kothare, 2008, Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus, J. Clin. Pharmacol., 48, 1389, 10.1177/0091270008323750 · DOI
  87. Krug, 2017, Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection, Clin. Transl. Sci., 10, 404, 10.1111/cts.12479 · DOI
  88. Lee, 2016, Multiplexed Quantification of Proglucagon-Derived Peptides by Immunoaffinity Enrichment and Tandem Mass Spectrometry after a Meal Tolerance Test, Clin. Chem., 62, 227, 10.1373/clinchem.2015.244251 · DOI
  89. Li, 2011, The G protein-coupled bile acid receptor, TGR5, stimulates gallbladder filling, Mol. Endocrinol., 25, 1066, 10.1210/me.2010-0460 · DOI · Paper page
  90. Li, 2016, Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development, Expert Opin. Investig. Drugs, 25, 871, 10.1080/13543784.2016.1189530 · DOI
  91. Lim, 2019, Correlation Between Symptomatic Gastro-Esophageal Reflux Disease (GERD) and Erosive Esophagitis (EE) Post-vertical Sleeve Gastrectomy (VSG), Obes. Surg., 29, 207, 10.1007/s11695-018-3509-0 · DOI
  92. Lin, 2004, The effects of gastric surgery on systemic ghrelin levels in the morbidly obese, Arch. Surg., 139, 780, 10.1001/archsurg.139.7.780 · DOI
  93. Lin, 2012, Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor, Mol. Pharmacol., 82, 843, 10.1124/mol.112.079640 · DOI
  94. Lin, 2016, GPR142 Controls Tryptophan-Induced Insulin and Incretin Hormone Secretion to Improve Glucose Metabolism, PLoS ONE, 11, e0157298, 10.1371/journal.pone.0157298 · DOI
  95. Lin, 2018, GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function, Mol. Metab., 11, 205, 10.1016/j.molmet.2018.02.008 · DOI
  96. Liu, 2018, Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition, ACS Med. Chem. Lett., 9, 1082, 10.1021/acsmedchemlett.8b00305 · DOI
  97. Lu, 2017, Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40, Nat. Struct. Mol. Biol., 24, 570, 10.1038/nsmb.3417 · DOI · Paper page
  98. Lund, 2016, Evidence of Extrapancreatic Glucagon Secretion in Man, Diabetes, 65, 585, 10.2337/db15-1541 · DOI · Paper page
  99. Lundberg, 1982, Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility, Proc. Natl. Acad. Sci. USA, 79, 4471, 10.1073/pnas.79.14.4471 · DOI · Paper page
  100. Luo, 2012, A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents, PLoS ONE, 7, e46300, 10.1371/journal.pone.0046300 · DOI
  101. Luo, 2018, The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials, Clin. Drug Investig., 38, 1089, 10.1007/s40261-018-0707-4 · DOI
  102. Malhi, 2017, Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases, Curr. Opin. Pharmacol., 37, 80, 10.1016/j.coph.2017.09.008 · DOI
  103. Martin, 1996, Effects of somatostatin-28 on circulating concentrations of insulin and gut hormones in sheep, J. Endocrinol., 151, 107, 10.1677/joe.0.1510107 · DOI
  104. Matsumoto, 2018, DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats, J. Pharmacol. Exp. Ther., 367, 509, 10.1124/jpet.118.250019 · DOI
  105. McGavigan, 2017, TGR5 contributes to glucoregulatory improvements after vertical sleeve gastrectomy in mice, Gut, 66, 226, 10.1136/gutjnl-2015-309871 · DOI · Paper page
  106. Medeiros, 1994, Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11, Endocrinology, 134, 2088, 10.1210/endo.134.5.7908871 · DOI
  107. Meegalla, 2018, Discovery of a novel potent GPR40 full agonist, Bioorg. Med. Chem. Lett., 28, 720, 10.1016/j.bmcl.2018.01.013 · DOI
  108. Meneilly, 1993, The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide, Diabetes Care, 16, 110, 10.2337/diacare.16.1.110 · DOI
  109. Menon, 2018, Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial, Diabetes Care, 41, 2603, 10.2337/dc18-0755 · DOI
  110. Mentlein, 1993, Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV, Regul. Pept., 49, 133, 10.1016/0167-0115(93)90435-B · DOI · Paper page
  111. Miller, 2016, Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target, Trends Endocrinol. Metab., 27, 609, 10.1016/j.tem.2016.04.002 · DOI
  112. Miras, 2017, Measurement of hepatic insulin sensitivity early after the bypass of the proximal small bowel in humans, Obes. Sci. Pract., 3, 95, 10.1002/osp4.76 · DOI
  113. Mokadem, 2013, Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency, Mol. Metab., 3, 191, 10.1016/j.molmet.2013.11.010 · DOI · Paper page
  114. Mulvihill, 2018, Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism, Peptides, 100, 158, 10.1016/j.peptides.2017.11.023 · DOI
  115. Näslund, 1997, Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity, Int. J. Obes. Relat. Metab. Disord., 21, 387, 10.1038/sj.ijo.0800418 · DOI · Paper page
  116. Nasteska, 2014, Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions, Diabetes, 63, 2332, 10.2337/db13-1563 · DOI · Paper page
  117. Nauck, 2018, Incretin hormones: Their role in health and disease, Diabetes Obes. Metab., 20, 5, 10.1111/dom.13129 · DOI · Paper page
  118. Nauck, 2017, Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors, Circulation, 136, 849, 10.1161/CIRCULATIONAHA.117.028136 · DOI · Paper page
  119. Neary, 2005, Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively, Endocrinology, 146, 5120, 10.1210/en.2005-0237 · DOI · Paper page
  120. Neylon, 2013, Successful subcutaneous glucagon use for persistent hypoglycaemia in congenital hyperinsulinism, J. Pediatr. Endocrinol. Metab., 26, 1157
  121. Nørregaard, 2018, A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents, Diabetes Obes. Metab., 20, 60, 10.1111/dom.13034 · DOI · Paper page
  122. Nunez, 2014, Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies, PLoS ONE, 9, e92494, 10.1371/journal.pone.0092494 · DOI
  123. O’Carroll, 1992, Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28, Mol. Pharmacol., 42, 939, 10.1016/S0026-895X(25)09269-7 · DOI · Paper page
  124. Oh, 2014, A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice, Nat. Med., 20, 942, 10.1038/nm.3614 · DOI · Paper page
  125. Østergaard, 2018, Design of Y2 Receptor Selective and Proteolytically Stable PYY3-36 Analogues, J. Med. Chem., 61, 10519, 10.1021/acs.jmedchem.8b01046 · DOI
  126. Overton, 2006, Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents, Cell Metab., 3, 167, 10.1016/j.cmet.2006.02.004 · DOI · Paper page
  127. Pachanski, 2017, GPR40 partial agonists and AgoPAMs: Differentiating effects on glucose and hormonal secretions in the rodent, PLoS ONE, 12, e0186033, 10.1371/journal.pone.0186033 · DOI
  128. Patel, 1999, Somatostatin and its receptor family, Front. Neuroendocrinol., 20, 157, 10.1006/frne.1999.0183 · DOI · Paper page
  129. Patel, 1978, Somatostatin in hypothalamus, extrahypothalamic brain, and peripheral tissues of the rat, Endocrinology, 102, 523, 10.1210/endo-102-2-523 · DOI · Paper page
  130. Pellicciari, 2009, Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity, J. Med. Chem., 52, 7958, 10.1021/jm901390p · DOI · Paper page
  131. Penick, 1961, Depression of food intake induced in healthy subjects by glucagon, N. Engl. J. Med., 264, 893, 10.1056/NEJM196105042641801 · DOI
  132. Peukert, 2014, Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists, ACS Med. Chem. Lett., 5, 1114, 10.1021/ml500240d · DOI
  133. Pittner, 2004, Effects of PYY[3-36] in rodent models of diabetes and obesity, Int. J. Obes. Relat. Metab. Disord., 28, 963, 10.1038/sj.ijo.0802696 · DOI · Paper page
  134. Plamboeck, 2013, The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty, Am. J. Physiol. Gastrointest. Liver Physiol., 304, G1117, 10.1152/ajpgi.00035.2013 · DOI · Paper page
  135. Pocai, 2012, Unraveling oxyntomodulin, GLP1's enigmatic brother, J. Endocrinol., 215, 335, 10.1530/JOE-12-0368 · DOI
  136. Pocai, 2009, Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice, Diabetes, 58, 2258, 10.2337/db09-0278 · DOI · Paper page
  137. Polonsky, 1983, Plasma somatostatin 28 increases in response to feeding in man, J. Clin. Invest., 71, 1514, 10.1172/JCI110907 · doi:10.1172/jci110907
  138. Rangwala, 2019, A Long-Acting PYY3-36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates, Cell Metab., 29, 837, 10.1016/j.cmet.2019.01.017 · DOI
  139. Rao, 2011, GIP and bariatric surgery, Obes. Surg., 21, 244, 10.1007/s11695-010-0305-x · DOI
  140. Ratner, 2016, Effects of Peripheral Neurotensin on Appetite Regulation and Its Role in Gastric Bypass Surgery, Endocrinology, 157, 3482, 10.1210/en.2016-1329 · DOI
  141. Ratner, 2019, Long-Acting Neurotensin Synergizes With Liraglutide to Reverse Obesity Through a Melanocortin-Dependent Pathway, Diabetes, 68, 1329, 10.2337/db18-1009 · DOI
  142. Rigamonti, 2011, Effect of somatostatin infusion on peptide YY secretion: studies in the acute and recovery phase of anorexia nervosa and in obesity, Eur. J. Endocrinol., 165, 421, 10.1530/EJE-11-0312 · DOI
  143. Ritter, 2016, G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges, J. Med. Chem., 59, 3579, 10.1021/acs.jmedchem.5b01198 · DOI
  144. Rudenko, 2019, The aromatic amino acid sensor GPR142 controls metabolism through balanced regulation of pancreatic and gut hormones, Mol. Metab., 19, 49, 10.1016/j.molmet.2018.10.012 · DOI
  145. Ryan, 2014, FXR is a molecular target for the effects of vertical sleeve gastrectomy, Nature, 509, 183, 10.1038/nature13135 · DOI · Paper page
  146. Salehi, 2016, Mechanisms of surgical control of type 2 diabetes: GLP-1 is the key factor-Maybe, Surg. Obes. Relat. Dis., 12, 1230, 10.1016/j.soard.2016.05.008 · DOI
  147. Salehi, 2019, Beta-cell sensitivity to insulinotropic gut hormones is reduced after gastric bypass surgery, Gut, 68, 1838, 10.1136/gutjnl-2018-317760 · DOI
  148. Salem, 2016, Glucagon increases energy expenditure independently of brown adipose tissue activation in humans, Diabetes Obes. Metab., 18, 72, 10.1111/dom.12585 · DOI · Paper page
  149. Schalla, 2019, Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges, Curr. Diab. Rep., 19, 102, 10.1007/s11892-019-1211-9 · DOI
  150. Schellekens, 2010, Lean mean fat reducing “ghrelin” machine: hypothalamic ghrelin and ghrelin receptors as therapeutic targets in obesity, Neuropharmacology, 58, 2, 10.1016/j.neuropharm.2009.06.024 · DOI
  151. Schilperoort, 2018, The GPR120 agonist TUG-891 promotes metabolic health by stimulating mitochondrial respiration in brown fat, EMBO Mol. Med., 10, e8047, 10.15252/emmm.201708047 · DOI
  152. Schmidt, 2014, Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men, Am. J. Physiol. Endocrinol. Metab., 306, E1248, 10.1152/ajpendo.00569.2013 · DOI
  153. Seeley, 2015, The role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetes, Cell Metab., 21, 369, 10.1016/j.cmet.2015.01.001 · DOI · Paper page
  154. Semple, 2011, Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control, Bioorg. Med. Chem. Lett., 21, 3134, 10.1016/j.bmcl.2011.03.007 · doi:10.1016/j.bmcl.2011.03.007
  155. Shankar, 2018, Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes, Diabetes, 67, 1105, 10.2337/db17-1331 · DOI
  156. Shen, 1982, Human somatostatin I: sequence of the cDNA, Proc. Natl. Acad. Sci. USA, 79, 4575, 10.1073/pnas.79.15.4575 · DOI · Paper page
  157. Sheng, 2018, Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design, Bioorg. Med. Chem. Lett., 28, 2599, 10.1016/j.bmcl.2018.06.047 · doi:10.1016/j.bmcl.2018.06.047
  158. Shi, 2018, Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists, J. Med. Chem., 61, 681, 10.1021/acs.jmedchem.7b00982 · DOI
  159. Sjöström, 2013, Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery, J. Intern. Med., 273, 219, 10.1111/joim.12012 · DOI · Paper page
  160. Sparks, 2017, Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist, Bioorg. Med. Chem. Lett., 27, 1278, 10.1016/j.bmcl.2017.01.034 · DOI
  161. Sumida, 2018, Current and future pharmacological therapies for NAFLD/NASH, J. Gastroenterol., 53, 362, 10.1007/s00535-017-1415-1 · DOI · Paper page
  162. Talsania, 2005, Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice, Endocrinology, 146, 3748, 10.1210/en.2005-0473 · DOI · Paper page
  163. Tan, 2004, Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome, J. Clin. Endocrinol. Metab., 89, 4162, 10.1210/jc.2004-0835 · DOI
  164. Tan, 2017, The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers, J. Clin. Endocrinol. Metab., 102, 2364, 10.1210/jc.2017-00469 · DOI · Paper page
  165. Tatemoto, 1982, Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion, Proc. Natl. Acad. Sci. USA, 79, 2514, 10.1073/pnas.79.8.2514 · DOI · Paper page
  166. Tatemoto, 1980, Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides, Nature, 285, 417, 10.1038/285417a0 · DOI · Paper page
  167. Tillner, 2019, A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials, Diabetes Obes. Metab., 21, 120, 10.1111/dom.13494 · DOI · Paper page
  168. Toda, 2013, Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes, ACS Med. Chem. Lett., 4, 790, 10.1021/ml400186z · DOI
  169. Tsilingiris, 2019, Remission of Type 2 Diabetes Mellitus after Bariatric Surgery: Fact or Fiction?, Int. J. Environ. Res. Public Health, 16, 3171, 10.3390/ijerph16173171 · DOI
  170. Tuttle, 2018, Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial, Lancet Diabetes Endocrinol., 6, 605, 10.1016/S2213-8587(18)30104-9 · DOI · Paper page
  171. van den Hoek, 2004, PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet, Diabetes, 53, 1949, 10.2337/diabetes.53.8.1949 · DOI
  172. Vilsbøll, 2003, The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype, J. Clin. Endocrinol. Metab., 88, 4897, 10.1210/jc.2003-030738 · DOI · Paper page
  173. Vu, 2001, Effect of somatostatin on postprandial gallbladder relaxation, Clin. Physiol., 21, 25, 10.1046/j.1365-2281.2001.00297.x · doi:10.1046/j.1365-2281.2001.00297.x
  174. Wacker, 2014, Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119, J. Med. Chem., 57, 7499, 10.1021/jm501175v · DOI
  175. Wewer Albrechtsen, 2016, Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma, EBioMedicine, 7, 112, 10.1016/j.ebiom.2016.03.034 · DOI
  176. Willard, 2012, Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin, Mol. Pharmacol., 82, 1066, 10.1124/mol.112.080432 · DOI
  177. Wilson, 2016, Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes, Bioorg. Med. Chem. Lett., 26, 2947, 10.1016/j.bmcl.2016.04.018 · DOI
  178. Wilson-Pérez, 2013, Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency, Diabetes, 62, 2380, 10.2337/db12-1498 · DOI · Paper page
  179. Wilson-Pérez, 2013, The effect of vertical sleeve gastrectomy on food choice in rats, Int. J. Obes., 37, 288, 10.1038/ijo.2012.18 · DOI
  180. Winters, 2018, Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes, Bioorg. Med. Chem. Lett., 28, 841, 10.1016/j.bmcl.2018.02.013 · DOI
  181. Yamada, 2018, Weekly Versus Daily Dipeptidyl Peptidase 4 Inhibitor Therapy for Type 2 Diabetes: Systematic Review and Meta-analysis, Diabetes Care, 41, e52, 10.2337/dc17-2095 · doi:10.2337/dc17-2095
  182. Yamada, 2018, Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study, Adv. Ther., 35, 367, 10.1007/s12325-018-0668-2 · DOI
  183. Yousseif, 2014, Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans, Obes. Surg., 24, 241, 10.1007/s11695-013-1066-0 · DOI · Paper page
  184. Yu, 2013, Aminopyrazole-Phenylalanine Based GPR142 Agonists: Discovery of Tool Compound and in Vivo Efficacy Studies, ACS Med. Chem. Lett., 4, 829, 10.1021/ml4000854 · DOI
  185. Zhang, 2017, Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes, ACS Med. Chem. Lett., 8, 947, 10.1021/acsmedchemlett.7b00233 · doi:10.1021/acsmedchemlett.7b00233

Cited by

See all 83

Metadata

Authors
Gimeno, R. E., Briere, D. A., & Seeley, R. J.
Venue
Cell Metabolism
Publisher
Elsevier BV
Published
2020-04
Volume
31
Issue
4
Pages
679-698
ISSN
1550-4131
Cited by
83
References
64
Language
en
Licence
Funders
  • Sanofi
  • Zafgen
  • Pfizer
  • Novo Nordisk

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Leveraging the Gut to Treat Metabolic Disease. https://app.cochat.ai/papers/10.1016/j.cmet.2020.02.014
The paper
Gimeno, R. E., Briere, D. A., & Seeley, R. J. (2020). Leveraging the Gut to Treat Metabolic Disease. Cell Metabolism. https://doi.org/10.1016/j.cmet.2020.02.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.